Cencora has climbed 161.7% over the past 5 years, yet at a last close of US$305.06 both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiple checks still point to the stock trading at a discount, with the DCF implying it may be 39.3% undervalued.

• A 161.7% 5 year return suggests Cencora has already rewarded long term holders, so any remaining undervaluation matters more for new money considering the stock today.
• Expectations around how reliably Cencora can convert revenue into cash flow can support the current valuation. However, any pressure on margins or large new capital needs may limit how much of the implied discount is realised.
• Cencora screens as undervalued on most of Simply Wall St’s checks, with a high value score of 5 out of 6 suggesting the broader signals lean toward the shares being cheap rather than fully priced.

The issue now is whether the apparent discount in Cencora’s intrinsic value and multiples still offers a comfortable margin of safety after such a strong multi year run.

Is Cencora a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model values Cencora by projecting the cash it could return to shareholders and discounting it back to today. On the latest twelve month numbers, Cencora generated about $1.66b in free cash flow, and the model assumes these cash flows continue growing rather than shrinking. Based on that profile, the 2 Stage Free Cash Flow to Equity approach points to an estimated intrinsic value of about $502 per share.

Compared with the recent share price of $305.06, the DCF output suggests Cencora appears undervalued, with the model implying a 39.3% discount. That gap depends on the company sustaining healthy free cash flow over time, so any sustained pressure on margins or heavier reinvestment needs could bring the intrinsic value estimate closer to the market price.

On this DCF view, Cencora stock currently appears undervalued relative to the cash flows analysts expect it to generate.

Our Discounted Cash Flow (DCF) analysis suggests Cencora is undervalued by 39.3%. Track this in your watchlist or portfolio, or discover 38 more high quality undervalued stocks.

Is Cencora a Bargain on Earnings?

The P/E ratio suits Cencora because earnings remain a core reference point for how investors are pricing the business today. Cencora currently trades on a P/E of about 23.3x, compared with roughly 25.5x for the wider Healthcare industry and around 30.2x for its peer group. That already places the stock at a discount to sector and peer averages.

On Simply Wall St’s fair P/E estimate of about 27.0x, which reflects the company’s profile relative to its sector and risk, Cencora’s current multiple is lower than the level this framework would expect. The gap between the current 23.3x and the fair 27.0x suggests the market is pricing Cencora’s earnings more cautiously than both peers and the model’s blended benchmark.

On the P/E measure, Cencora stock appears undervalued compared with where this framework would typically expect it to trade.

The Cencora Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the earlier Cencora valuation checks leave off by spelling out which assumptions on Cencora's growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than its current price. Each narrative sets out a fair value as a thesis about Cencora's business that can be tracked over time, and these sit together on Simply Wall St's Community page.

One of the top community narratives on Cencora: roughly fairly valued

"This narrative explores a more pessimistic perspective on Cencora compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts…"

Do you think there's more to the story for Cencora? Head over to our Community to see what others are saying!

The Bottom Line

For Cencora, both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple view currently point in the same direction, with the stock screening as undervalued rather than fully priced. That alignment, backed by broadly supportive valuation checks, suggests the market is not placing a premium on the company’s cash generation or current P/E relative to peers. From here, the focus is on whether Cencora can maintain the cash flow and earnings profile that underpins those models, or whether margin pressure and reinvestment needs reduce more of that apparent discount over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.